| Domain | Current evidence | Quantitative detail | Evidence strength |
|---|---|---|---|
| Identifiers | POT1 tumor predisposition syndrome corresponds to MONDO_0014368 (“tumor predisposition syndrome 3”); OMIM 615848 is cited in recent case literature and GeneReviews-derived sources. | MONDO_0014368; OMIM 615848 | Moderate for MONDO disease mapping; moderate for OMIM based on disease resources and recent reports (pqac-00000000, pqac-00000001) |
| Inheritance / penetrance | Inherited in an autosomal dominant manner; penetrance remains unknown and phenotype is incompletely defined. | 50% transmission risk to offspring; de novo proportion unknown | Moderate-strong from GeneReviews-derived summaries and 2024 cohort framing (pqac-00000001, pqac-00000012) |
| Core tumor spectrum | Best-supported associated malignancies are cutaneous melanoma, chronic lymphocytic leukemia, angiosarcoma (especially cardiac), and glioma. Other tumors have been proposed but remain less certain. | Melanoma onset reported from 15-80 years; most cancers diagnosed in adulthood | Strong for core spectrum; weaker for expanded spectrum (pqac-00000001, pqac-00000012, pqac-00000005) |
| 2024 family cohort | A recent three-family report suggests a broader phenotype but should be interpreted cautiously. | 37 tested relatives/individuals; 22 carriers; 51.4% female; median age 46 years (22-81) | Moderate, hypothesis-generating cohort evidence (pqac-00000012) |
| Familial CLL evidence | Familial CLL association is supported by rare germline POT1 variants segregating in affected families; one variant also showed case-control enrichment. | 4/66 CLL families with co-segregating POT1 LoF/likely deleterious variants; p.Gln376Arg OR 3.61, P=0.009 in 1,083 cases vs 5,854 controls | Strong for CLL association (pqac-00000016) |
| Molecular diagnosis | Diagnosis is established by identifying a heterozygous germline pathogenic/likely pathogenic POT1 variant in an appropriate clinical context. Sequence analysis plus del/dup analysis are recommended approaches. | Heterozygous germline pathogenic POT1 variant required | Strong for current diagnostic approach (pqac-00000001, pqac-00000002) |
| Mechanism | POT1 dysfunction impairs shelterin-mediated telomere regulation. Human stem-cell and other models support telomere elongation and increased proliferative capacity as central effects; DNA damage signaling appears variant- and context-dependent rather than uniform. | Engineered hESC/HSC models showed telomere elongation without overt telomere damage for tested variants; mouse/tumor models show RPA-ATR DDR involvement in some contexts | Strong mechanistic support, but variant-specific heterogeneity remains (pqac-00000013, pqac-00000014, pqac-00000017, pqac-00000018) |
| Surveillance | Expert-opinion surveillance includes dermatologic skin examination, annual CBC with differential, annual physical examination, and MRI-based screening individualized by personal/family history. | Skin exam every 6 months from age 18, or every 3-6 months in higher-risk melanoma settings; annual CBC/physical exam; whole-body MRI annually in selected families; brain MRI every 1-2 years when indicated | Moderate, largely expert-opinion due to limited penetrance data (pqac-00000001, pqac-00000006, pqac-00000015) |
| Therapy / management | No syndrome-specific targeted therapy is established; management is standard-of-care treatment for each tumor plus risk-reduction and cascade testing. | No POT1-TPD-specific interventional trials identified; exposure avoidance includes tanning beds/unprotected sun and unnecessary diagnostic radiation | Moderate for absence of syndrome-specific therapy; strong for current standard management framing (pqac-00000012, pqac-00000006) |
| Models | Disease biology has been modeled in human embryonic stem cells, hematopoietic stem cells, mouse embryonic fibroblasts, Pot1a R117C knock-in mice, and serially passaged Pot1b-null sarcoma models. | Pot1a+/ki mice developed a high incidence of angiosarcomas including cardiac angiosarcoma; serial Pot1b-null tumors developed hyper-elongated telomeres | Strong for availability and utility of model systems, with known mouse-human Pot1 biology differences (pqac-00000013, pqac-00000014, pqac-00000018) |


*Table: This table summarizes the most actionable current evidence for POT1 tumor predisposition syndrome, highlighting what is well-supported versus still uncertain. It is useful as a compact reference for identifiers, diagnosis, mechanism, surveillance, and the strongest human and model-system data.*